| Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort KB Gecse, BD Lovász, K Farkas, J Banai, L Bene, B Gasztonyi, ... Journal of Crohn's and Colitis 10 (2), 133-140, 2016 | 220 | 2016 |
| Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in … LS Kiss, T Szamosi, T Molnar, P Miheller, L Lakatos, A Vincze, K Palatka, ... Alimentary pharmacology & therapeutics 34 (8), 911-922, 2011 | 195 | 2011 |
| Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis–experiences from a single center K Farkas, M Rutka, A Bálint, F Nagy, R Bor, Á Milassin, Z Szepes, ... Expert opinion on biological therapy 15 (9), 1257-1262, 2015 | 104 | 2015 |
| Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease PL Lakatos, LS Kiss, K Palatka, I Altorjay, P Antal-Szalmas, E Palyu, ... Inflammatory bowel diseases 17 (3), 767-777, 2011 | 101 | 2011 |
| Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis K Farkas, M Rutka, PA Golovics, Z Végh, BD Lovász, T Nyári, KB Gecse, ... Journal of Crohn's and Colitis 10 (11), 1273-1278, 2016 | 98 | 2016 |
| Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy T Molnár, PL Lakatos, K Farkas, F Nagy, Z Szepes, P Miheller, G Horváth, ... Alimentary pharmacology & therapeutics 37 (2), 225-233, 2013 | 98 | 2013 |
| Pregnancy outcome in patients with inflammatory bowel disease according to the activity of the disease and the medical treatment: a case–control study T Molnár, K Farkas, F Nagy, PL Lakatos, P Miheller, T Nyári, G Horváth, ... Scandinavian journal of gastroenterology 45 (11), 1302-1306, 2010 | 89 | 2010 |
| Fecal MMP-9: a new noninvasive differential diagnostic and activity marker in ulcerative colitis A Annaházi, T Molnár, K Farkas, A Rosztóczy, F Izbéki, K Gecse, O Inczefi, ... Inflammatory bowel diseases 19 (2), 316-320, 2013 | 88 | 2013 |
| Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics MD Michael, A Bálint, BD Lovász, L Gulácsi, B Strbák, PA Golovics, ... The European Journal of Health Economics 15, 121-128, 2014 | 85 | 2014 |
| H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy JF Rahier, P Papay, J Salleron, S Sebastian, M Marzo, L Peyrin-Biroulet, ... Gut 60 (4), 456-462, 2011 | 84 | 2011 |
| Do not forget the stool examination!—cutaneous and gastrointestinal manifestations of Blastocystis sp. infection A Bálint, I Dóczi, L Bereczki, R Gyulai, M Szűcs, K Farkas, E Urbán, ... Parasitology research 113, 1585-1590, 2014 | 80 | 2014 |
| New therapeutic targets in ulcerative colitis: the importance of ion transporters in the human colon K Farkas, S Yeruva, Z Rakonczay Jr, L Ludolph, T Molnár, F Nagy, ... Inflammatory bowel diseases 17 (4), 884-898, 2011 | 77 | 2011 |
| Preserved Na+/H+ exchanger isoform 3 expression and localization, but decreased NHE3 function indicate regulatory sodium transport defect in ulcerative colitis† S Yeruva, K Farkas, J Hubricht, K Rode, B Riederer, O Bachmann, ... Inflammatory bowel diseases 16 (7), 1149-1161, 2010 | 74 | 2010 |
| Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard‐dose subcutaneous maintenance therapy U Kopylov, J Hanzel, C Liefferinckx, D De Marco, N Imperatore, N Plevris, ... Alimentary pharmacology & therapeutics 52 (1), 135-142, 2020 | 68 | 2020 |
| Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy K Farkas, PL Lakatos, F Nagy, Z Szepes, P Miheller, M Papp, K Palatka, ... Scandinavian Journal of Gastroenterology 48 (12), 1394-1398, 2013 | 66 | 2013 |
| Prediction of short-and medium-term efficacy of biosimilar infliximab therapy. Do trough levels and antidrug antibody levels or clinical and biochemical markers play the more … L Gonczi, Z Vegh, PA Golovics, M Rutka, KB Gecse, R Bor, K Farkas, ... Journal of Crohn's and Colitis 11 (6), 697-705, 2017 | 61 | 2017 |
| Long-term efficacy, safety, and immunogenicity of biosimilar infliximab after one year in a prospective nationwide cohort L Gonczi, KB Gecse, Z Vegh, Z Kurti, M Rutka, K Farkas, PA Golovics, ... Inflammatory bowel diseases 23 (11), 1908-1915, 2017 | 60 | 2017 |
| Response to first intravenous steroid therapy determines the subsequent risk of colectomy in ulcerative colitis patients T Molnár, K Farkas, T Nyári, Z Szepes, F Nagy, T Wittmann J Gastrointestin Liver Dis 20 (4), 359-363, 2011 | 58 | 2011 |
| Polyunsaturated fatty acids synergize with lipid droplet binding thalidomide analogs to induce oxidative stress in cancer cells LG Puskás, LZ Fehér, C Vizler, F Ayaydin, E Rásó, E Molnár, I Magyary, ... Lipids in health and disease 9, 1-9, 2010 | 57 | 2010 |
| Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease É Pallagi-Kunstár, K Farkas, Z Szepes, F Nagy, M Szűcs, R Kui, R Gyulai, ... World Journal of Gastroenterology: WJG 20 (17), 5031, 2014 | 55 | 2014 |
